TERNS PHARMACEUTICALS INC (TERN)

US8808811074 - Common Stock

6.16  0 (0%)

After market: 6.16 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

TERNS PHARMACEUTICALS INC

NASDAQ:TERN (3/27/2024, 8:00:01 PM)

After market: 6.16 0 (0%)

6.16

0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap380.63M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

TERN Daily chart

Company Profile

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 46 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity. Its product pipeline includes TERN-701, TERN-501, TERN-601 and TERN-101. ItsTERN-701 is an oral, potent, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) specifically targeting the ABL myristoyl pocket for chronic myeloid leukemia. The TERN-501 is its highly selective thyroid hormone receptor beta (THR-b) agonist for non-alcoholic steatohepatitis (NASH) in Phase IIa clinical development. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist for metabolic diseases such as obesity. TERN-101 is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver.

Company Info

TERNS PHARMACEUTICALS INC

1065 East Hillsdale Blvd., Suite 100, Suite 100

Foster City CALIFORNIA 94404

P: 16505255535

CEO: Senthil Sundaram

Employees: 46

Website: https://ternspharma.com/

TERN News

News Image3 days ago - InvestorPlaceWall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich

Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.

News Image10 days ago - Market News VideoTerns Pharmaceuticals (TERN) Shares Cross Below 200 DMA
News Image11 days ago - The Motley FoolMadrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

News Image13 days ago - InvestorPlaceTERN Stock Earnings: Terns Pharma Meets EPS for Q4 2023

TERN stock results show that Terns Pharma met analyst estimates for earnings per share the fourth quarter of 2023.

News Image13 days ago - BusinessInsiderTERN Stock Earnings: Terns Pharma Meets EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Terns Pharma (NASDAQ:TERN) just reported results for the fourth quarter of 2023...

News Image14 days ago - Terns Pharmaceuticals, Inc.Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

TERN Twits

Here you can normally see the latest stock twits on TERN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example